Skip to main content
Fig. 1 | Infectious Agents and Cancer

Fig. 1

From: Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

Fig. 1

Figure shows the survey proposed by Clinician every month during treatment period. According to possible changes in health status perceived by the patient as well as any relevant clinical and laboratory condition, adverse events notification were reported and discussed with Hospital Pharmacist and entered in the online based Italian system for adverse drug reaction notifications

Back to article page